

*This press release may not be published or distributed, directly or indirectly, in or into the United States, Australia, Japan, Canada, Hong Kong, New Zealand, Singapore or South Africa or any other jurisdiction where such action is subject to legal restrictions.*

Press Release  
Lund on 17 March 2016

### **Updated time plan for the acquisition of Zymetech and the rights issue**

**The estimated date for the completion of Enzymatica AB (publ)'s (the "Company") acquisition of Zymetech ehf. is 1 April 2016 as the Company and the sellers estimate that the conditions for completion will be satisfied during March 2016. The time plan for the rights issue means inter alia that an extra general meeting will be held on 14 April 2016 according to notice that has been published and that the last day of trading including subscription rights is 15 April 2016. The first day of trading excluding subscription rights is 18 April 2016.**

On 28 January 2016, the Company's acquisition of the Icelandic company Zymetech ehf was announced. The transaction was approved by the extra general meeting in the Company on 15 February 2016. The Company and the sellers are now planning to complete the transaction on 1 April 2016 as the remaining conditions for completion are estimated to be satisfied during March 2016, including the obtainment of necessary governmental approvals.

#### **Time plan**

1 April	Completion of the Zymetech acquisition
14 April	Extraordinary shareholders' meeting
15 April	Last day of trading inclusive subscription rights
18 April	First day of trading exclusive subscription rights
19 April	Record date for participation in the rights issue
20 April	Estimated date for publication of the prospectus
21 April – 3 May	Trading in subscription rights
21 April – 6 May	Subscription period
11 May	Estimated day for announcement of outcome of the rights issue

Further details on participation in the rights issue is set out in the notice that has been published and coming prospectus.

#### **For more information, contact:**

---

Fredrik Lindberg, CEO Enzymatica AB  
Tel: +46 (0)708-86 53 70 | Email: [fredrik.lindberg@enzymatica.com](mailto:fredrik.lindberg@enzymatica.com)

#### **About Enzymatica AB**

Enzymatica is a life science company who develops and sells medical device products against infectious-related diseases. Over a short period the company has developed a unique oral spray for

colds, ColdZyme<sup>®</sup>, and launched it on six markets. The product has become one of the leading articles for colds in Swedish pharmacies. Enzymatica's strategy is to continue growing by strengthening its position in existing markets and to expand to more geographical markets through well-established partners. The company is headquartered in Lund, Sweden and is listed on Nasdaq First North. For more information, please visit [www.enzymatica.com](http://www.enzymatica.com).

Enzymatica's certified adviser is Erik Penser Bankaktiebolag.

Enzymatica's certified adviser is Erik Penser Bankaktiebolag.

### **Important information**

*The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in Enzymatica AB (publ). Any invitation to the persons concerned to subscribe for shares in Enzymatica AB (publ) will only be made through the prospectus that Enzymatica AB (publ) estimates to publish on or about 20 April 2016.*

*This press release may not be published or distributed, directly or indirectly in or into the United States, Australia, Japan, Canada, Hong Kong, New Zealand, Singapore or South Africa or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to what follows from Swedish law. Nor may the information in this press release be forwarded, reproduced or disclosed in such a manner that contravenes such restrictions or would require such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.*

*No subscription rights, interim shares or new shares have been registered, and will not be registered, under the United States Securities Act of 1933 ("Securities Act") or securities legislation in any other state or other jurisdiction in the United States and may not be offered, subscribed, sold or transferred, directly or indirectly within the United States, other than pursuant to an exemption from the registration requirements of the Securities Act and in accordance with securities laws in relevant state or other jurisdiction in the United States.*

*This press release may contain forward-looking statements which reflect Enzymatica AB (publ):s current view on future events and financial and operational development. Words such as "intend", "expect", "anticipate", "may", "believe", "plan", "estimate" and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties because they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the real outcome could differ materially from the forward-looking statements.*